Share This Author
The discovery of AZD9164, a novel muscarinic M3 antagonist.
The design of a novel series of muscarinic receptor antagonists leading to AZD8683, a potential inhaled treatment for COPD.
Pharmacological profile and efficacy of GLPG1690, a novel ATX inhibitor for COPD treatment
GLPG1690, a potent and selective ATX inhibitor, displays a strong overall developability profile, supporting the progression towards First-in-Human studies and pointing to a novel therapeutic area for this target.
Oral S-Nitrosoglutathione Reductase Inhibitors Attenuate Pulmonary Inflammation And Decrease Airspace Enlargement In Experimental Models Of Chronic Obstructive Pulmonary Disease
Inhaled calcium salts inhibit tobacco smoke-induced inflammation by modulating expression of chemokines and cytokines.
Quantitation of hydroxyproline in a mouse model of bleomycin-induced lung fibrosis: comparison with histological analysis
Reduced Neutrophilic Airway Inflammation By Inhalation Of Dry Powder Calcium Salts In A Mouse Model Of Sub-Chronic Tobacco Smoke Exposure
Inhaled Calcium Salts Reduce Acute Airway Inflammation Associated With Tobacco Smoke Exposure
A robust translational model of acute exacerbations in the tobacco-smoke and poly IC treated mouse
- V. Russell, P. Woodman, A. Connolly, D. Spicer, J. Dlugozima, A. Young
- Medicine, Biology
- 1 September 2012
Addition of PIC markedly enhanced the inflammatory response which was sensitive to both steroids and roflumilast, mimicking features of human COPD.
The Effect of the CXCR1/2 Antagonist SCH257123 in a Mouse Model of Severe Asthma
This study has investigated the effect of a CXCR1/2 antagonist, SCH257123 (SCH), in a mouse severe asthma model known to be steroid insensitive, and found it to be beneficial in both the prevention and treatment of severe asthma patient phenotypes.